Sanuwave Health Announces Preliminary Revenue Results for the Second Quarter 2025 (Ended June 30, 2025)
MWN-AI** Summary
Sanuwave Health, Inc. (NASDAQ: SNWV) has announced preliminary revenue results for the second quarter of 2025, reporting between $10.1 million and $10.2 million. This marks the highest quarterly revenue in the company's history for Q2 and reflects a robust growth rate of 41% to 42% compared to the same quarter in 2024. For the first half of 2025, revenues have surged by 50% to 51% versus the first half of 2024.
Morgan Frank, the CEO of Sanuwave, expressed satisfaction in being on track with guidance provided in their previous earnings release. He emphasized that the first half of 2025 has been a significant transition period as the company has undergone substantial operational changes, including staffing a new head of sales and a national accounts manager aimed at capturing larger market opportunities. With plans to increase their sales team to 13 members, all national sales territories are now covered for the first time under Frank's leadership.
This operational overhaul has been likened to "taking the plane apart and putting it back together while flying it," according to Frank, who praised the team for their accomplishments during this challenging phase. Sanuwave’s focus remains on developing FDA-approved wound care products, leveraging patented technologies designed for skin, musculoskeletal, and vascular tissue repair.
The company plans to release its complete Q2 results on or around August 8, 2025, which will provide additional insights into their financial performance and strategic direction. However, the preliminary results are subject to adjustment based on the finalization of the company's financial close process. As always, potential investors are reminded that forward-looking statements carry inherent risks and uncertainties.
MWN-AI** Analysis
Sanuwave Health (NASDAQ: SNWV) has announced preliminary revenue results for Q2 2025, indicating a promising trajectory for the company. With revenue projected between $10.1 million and $10.2 million, marking a robust year-over-year increase of 41% to 42%, this reflects the highest quarterly revenue in Sanuwave’s history. Additionally, the first half of 2025 revenue exhibits impressive growth of approximately 50-51% compared to the same period in 2024.
CEO Morgan Frank highlights the company's strategic adjustments, including the appointment of a new sales head and enhanced commercial operations. As the team expands to include 13 salespeople and a dedicated national accounts manager, Sanuwave appears poised to leverage these resources effectively in tapping larger market opportunities. The operational restructuring and aggressive staffing appear to be strategic moves catering to projected market growth, particularly in regenerative medicine.
Investors should view the preliminary results as a potential bullish indicator, given Sanuwave’s successful alignment with its guidance and its commitment to maintaining momentum in growth. However, it is crucial to maintain caution as the company moves through its financial close process; adjustments to preliminary revenue figures are possible.
Looking forward, the anticipated Q2 full results, to be released on August 8, 2025, will provide more comprehensive insights into the company’s financial health and execution of its strategic vision.
In light of these developments, current investors might consider holding or gradually accumulating shares, while new investors should closely monitor earnings releases and market reactions before committing. Overall, Sanuwave's growth trajectory presents a compelling case for consideration within the medical device and regenerative medicine sectors, albeit with due diligence around potential risks and market volatility.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Sanuwave is pleased to announce preliminary revenues of $10.1 million to $10.2 million for the second quarter ended June 30, 2025. This represents the highest Q2 quarterly revenues in Company history.
Q2 2025 revenue increased between 41% and 42% compared to Q2 2024.
First half of 2025 revenue increased 50-51% vs first half of 2024.
EDEN PRAIRIE, Minn., July 14, 2025 (GLOBE NEWSWIRE) -- Sanuwave Health, Inc. (the "Company" or "Sanuwave”) (NASDAQ: SNWV), a leading provider of next-generation FDA-approved wound care products, today announced that revenues for the second quarter of 2025 are expected to be in the range of $10.1 to $10.2 million, an increase of 41% to 42% over Q2 2024. This number is within the range of guidance given in the Company’s Q1 2025 earnings release issued on May 9, 2025.
“We’re pleased to once more be on guidance and on track for Q2 and for the first half of 2025,” said CEO Morgan Frank. “As we mentioned last quarter, the first half of 2025 has been a transition period for the company as we have added a new head of sales and now a new head of commercial operations. Q2 was really the “max transition” period as we have been staffing up rapidly and will, in July, reach 13 sales people and for the first time in my tenure as CEO have all of our national sales territories covered. We have also added a key national accounts manager to be our dedicated “elephant hunter” in order to better pursue some of the larger opportunities in our market. This has been a period of taking the plane apart and putting it back together all while flying it quite fast, and the team has come through in phenomenal fashion. We’re all very excited about what we’re building here, our pipeline, and the prospects for the year and years ahead. The Company plans to release its full Q2 results on or around August 8th, 2025 and we look forward to speaking with you then to give you a more complete update on our quarterly performance and our future plans and guidance.”
The preliminary revenue results described herein are based on management’s initial analysis of the second quarter ended June 30, 2025, and may be subject to adjustments based on the Company’s completion of its quarter-end financial close process.
About Sanuwave
Sanuwave Health is focused on the research, development, and commercialization of its patented, non-invasive and biological response-activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures.
Sanuwave’s end-to-end wound care portfolio of regenerative medicine products and product candidates help restore the body’s normal healing processes. Sanuwave applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, aesthetic/cosmetic, and cardiac/endovascular conditions.
Forward-Looking Statements
This press release may contain “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to future financial results, production expectations, plans for future business development activities and expectations regarding the impact of changes in tariff rates. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company’s ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the key risks, assumptions and factors that may affect operating results, performance and financial condition are risks associated with regulatory oversight, the Company’s ability to manage its capital resources, competition and the other factors discussed in detail in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to update any forward-looking statement.
Contact: investors@sanuwave.com
FAQ**
What strategies is Sanuwave Health Inc SNWV implementing to sustain the impressive 41-42% revenue growth observed in Q2 2025 compared to Q2 2024, and how will this impact its future financial outlook?
How does Sanuwave Health Inc SNWV plan to leverage its newly added sales personnel and national accounts manager to capitalize on market opportunities and further increase revenue going forward?
Given the company's significant revenue growth and recent staffing changes, what specific operational challenges has Sanuwave Health Inc SNWV faced during this transition period, and how have they been addressed?
What key performance indicators will Sanuwave Health Inc SNWV focus on during its upcoming Q2 results announcement, and how do these indicators align with the company's long-term strategic goals?
**MWN-AI FAQ is based on asking OpenAI questions about SANUWAVE Health Inc. (NASDAQ: SNWV).
NASDAQ: SNWV
SNWV Trading
-2.74% G/L:
$18.81 Last:
20,791 Volume:
$18.94 Open:
